ArticleArchives of rheumatology2025
Metabolic Syndrome and Metabolic Dysfunction-associated Steatotic Liver Disease in Fibromyalgia.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsFibromyalgia (FM) is a chronic disease characterized by widespread pain. An increased cardiovascular risk has been suggested in these patients. The aim was to investigate the cardiovascular risk factors in these patients. MATERIALS AND
methodsPatients with primary FM consecutively were prospectively recruited from a tertiary medical center in Taiwan. As the control group, individuals without FM who had undergone a health checkup examination were recruited. Their traditional cardiovascular risk factors, carotid intima-media thickness (IMT), and the presence of metabolic syndrome were then determined. Metabolic dysfunction-associated steatotic liver disease (MASLD) and the severity of hepatic steatosis (the Saverymuttu and Hamaguchi scores) were both determined by sonography. Multivariate logistic and linear regression were used to compare groups of subjects.
resultsA total of 66 FM patients and 116 controls were recruited. Between FM patients and controls, comparable cardiovascular risk factors were found, including carotid IMT and metabolic syndrome. FM patients had a higher proportion of central adiposity when compared with the controls, with an odds ratio of 6.1 (95% CI: 2.9, 13.1). Fibromyalgia patients had a more severe hepatic steatosis, if present, as determined by the Hamaguchi score. In female subjects, FM patients had a higher proportion of MASLD when compared with the controls, with an odds ratio of 2.8 (95% CI: 1.3, 6.1). The disease severity was associated with left IMT value and lipid blood levels in FM patients.
conclusionFibromyalgia patients had a higher proportion of central adiposity and more severe hepatic steatosis when compared with the controls. Those patients with more severe FM symptoms likely had a higher cardiovascular risk. Metabolic dysfunction-associated steatotic liver disease merits more attention in FM patients. Cite this article as: Chen C, Chen Y, Chen D, Yang S, Tang K. Metabolic syndrome and metabolic dysfunction-associated steatotic liver disease in fibromyalgia. Arch Rheumatol. 2025;40(4):452-458.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.